Abemaciclib suppresses cervical cancer cell, pancreatic ductal adenocarcinoma, prostate cancer, and TNBC cell growth by promoting apoptosis via the suppression of CDK4/6-Rb-E2F and mTOR pathways, overexpression of caspase-3, pro-apoptotic proteins, and cell cycle regulatory proteins (p53), as well as downregulation of apoptosis 2 inhibitor, X-linked inhibitor of apoptosis protein, and heat shock protein 60 (Eskiler et al. 2022; Alian et al. 2024). Here, HSPD1 is linked to prostate cancer.